Mediatorn 20mg 50 tablets — Made in Ukraine — Free Delivery

Brand: ARTERIUM
Product Code: Mediatorn
Availability: In Stock

$40.36

Add to Cart

Description

Product description

Mediatorn® is indicated for:

diseases of the peripheral nervous system (neuropathy, neuritis, polyneuritis and polyneuropathy, myelopolyradiculoneuritis);
myasthenia gravis and myasthenic syndrome of various etiologies;
bulbar paralysis and paresis;
memory impairment of various etiologies (Alzheimer's disease and other forms of senile mental impairment); mental retardation in children;
the recovery period of organic lesions of the central nervous system, accompanied by motor disorders;
in the complex therapy of multiple sclerosis and other forms of demyelinating diseases of the nervous system;
intestinal atony.

Compound

Active ingredient: ipidacrine.

1 tablet contains ipidacrine hydrochloride monohydrate, calculated as an anhydrous substance 20 mg.

Excipients: lactose monohydrate, potato starch; calcium stearate.

Contraindications

Hypersensitivity to ipidacrine and other components of the preparation;
epilepsy;
extrapyramidal disorders with hyperkinesis;
angina;
severe bradycardia;
bronchial asthma;
vestibular disorders;
mechanical obstruction of the intestines and urinary tract;
peptic ulcer of the stomach or duodenum in the acute stage;
pregnancy;
period of breastfeeding.

Mode of application

Mediatorn® tablets are used orally.

With neuritis - 1 tablet 2-3 times a day. The course of treatment is from 10-15 days for acute neuritis to 20-30 days for chronic neuritis. If necessary, the course of treatment should be repeated 2-3 times with an interval of 2-4 weeks until the maximum effect is achieved.

With myelopolyradiculoneuritis and paresis - 1 tablet 2-3 times a day for 30-40 days. Repeat courses of treatment many times with a break of 1-2 months until a therapeutic effect is achieved.

With myasthenia gravis and myasthenic syndromes - 1-2 tablets 2-3 times a day. In severe forms, the dose can be increased to 200 mg per day (2 tablets 5 times a day after 2-3 hours). Treatment course, alternating with classical anticholinesterase preparations.

With multiple sclerosis and other forms of demyelinating diseases of the nervous system, bulbar paralysis - 1 tablet 3-5 times a day for 60 days 2-3 times a year.

In Alzheimer's disease and other forms of senile mental impairment, start with a dose of 1-2 tablets per day, divided into 2 doses with a gradual increase in dose by 2 tablets per week to 6-10 tablets per day (2 tablets 3-5 times a day) . Duration of treatment - from 4 months to 1 year. Course therapy is possible - for 4-5 months with a break of 1-2 months.

With organic lesions of the central nervous system, accompanied by motor disorders - 1 tablet 2-3 times a day. The average course of treatment is 30 days. If necessary, the course of treatment can be repeated.

With intestinal atony - 1-3 tablets per day, distributing the dose into 3 doses. The course of treatment is 1-3 weeks.

Children over 12 years of age with mental retardation and diseases of the peripheral nervous system Mediatorn® should be prescribed 1 tablet (20 mg) 2-3 times a day. The course of treatment is 1-2 months (depending on the clinical picture).

Application features

The preparation contains lactose, so patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use it.

pregnant

Mediatorn® increases the tone of the uterus and can cause premature birth, therefore, during pregnancy, the use of the preparation is contraindicated.

During lactation, the use of the preparation is contraindicated.

Children

The preparation can be used in children over the age of 12 years.

Drivers

Mediatorn® can have a sedative effect, so care should be taken when using the preparation while driving.

Overdose

With severe intoxication, a cholinergic crisis may develop.

Symptoms: bronchospasm, lacrimation, increased sweating, pupillary constriction, nystagmus, increased peristalsis of the digestive tract, spontaneous defecation and urination, vomiting, jaundice, bradycardia, cardiac conduction disturbance, arrhythmia, lowering blood pressure, anxiety, anxiety, agitation, fear, ataxia , convulsions, coma, speech disorder, drowsiness, general weakness.

Treatment: symptomatic therapy. The use of m anticholinergics (atropine, cyclodol, metacin).

Adverse reactions

Mediatorn® is well tolerated. Possible side effects are associated with the excitation of m cholinergic receptors.

Interaction

Mediatorn® enhances the sedative effect in combination with preparations that suppress the central nervous system. The action and side effects are enhanced when used together with other cholinesterase inhibitors and m-cholinomimetic agents.

In patients with myasthenia gravis, the risk of developing a "cholinergic" crisis increases if Mediatorn® is used simultaneously with cholinergic agents. Risk of developing bradycardia if β-blockers are used before treatment with Meditorn®.

Mediatorn® can be used in combination with nootropic preparations.

Alcohol enhances the side effects of the preparation.

Cerebrolysin improves the mental impact of Mediatorn®.

Storage conditions

In original packaging at a temperature not exceeding 25°C. Keep out of the reach of children.

Shelf life - 2 years.

0 reviews

There are no reviews for this product.